Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 103,211

Document Document Title
WO/2014/146490A1
Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.  
WO/2014/151258A1
The present invention is directed to substituted pyridine derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives in the treatment of disorders mediated by c-fms kinase. The present invention ...  
WO/2014/150687A1
The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant and/or lactating woman for improving one or more characteristics in offspring, for example cognition and/or bone health. The carbohyd...  
WO/2014/152621A1
The present invention is directed to a compound of Formula (I): wherein: The present invention is directed to a compound of Formula (I): wherein: • n is an integer from 0-1; • X is CH2 when n is 0, or X is CH2 or oxygen when n is 1; ...  
WO/2014/147353A1
The invention relates to the use of 4-{3-[cis-hexahydrocyclopenta[C]pyrrole-2(1H)-yl]propoxy}ben zamide of formula (I): or of the acid or base addition salts thereof, which is pharmaceutically acceptable for treating neuropathic pain as ...  
WO/2014/146553A1
The present invention belongs to the field of pharmaceutical chemistry, and, in particular, disclosed therein are a flavonoid derivative and use thereof. Disclosed is a flavonoid derivative having the structure of general formula (I) or ...  
WO/2014/153172A1
Described herein are compounds of Formula (I-a) and (I-b), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT1 activity. Methods of using ...  
WO/2014/152144A1
Compounds of formula (I) and methods are provided for the treatment of disease or conditions in which modification of cholinergic, especially muscarinic receptor activity, has a beneficial effect.  
WO/2014/151387A1
Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the composition...  
WO/2014/153529A1
The invention provides modulators of the nociceptin receptor (NOP), including both agonists and antagonists. A compound of the invention can be a selective modulator of NOP with respect to the μ- and κ- opioid receptors (MOP and KOP), ...  
WO/2014/152589A1
The present invention is directed to a compound of Formula (I) or (la) The invention also relates to pharmaceutical compositions comprising compounds of Formula (I) or (la) and methods comprising administering of compounds of Formula (I)...  
WO/2014/151338A1
The present invention provides methods for treating or limiting development of multiple sclerosis by administering angiotensin peptides to a subject with multiple sclerosis or at risk of developing multiple sclerosis.  
WO/2014/144512A1
A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are meth...  
WO/2014/139443A1
Provided are a low immunogenicity human cell and a preparation method therefor. The cell is a modified human cell. Compared with a corresponding wild-type cell, the human leukocyte antigen (HLA) protein or polypeptide of surface of the c...  
WO/2014/144231A1
The invention relates to methods for treating stress sensitive condition. For instance a subject having or at risk of having a stress-sensitive condition may be treated with a growth hormone (GH) antagonist in an effective amount to trea...  
WO/2014/140086A1
The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: (I). In formula I the variables X1 is CH or N, X2 is O or S and where R1, R2, R3, R4 an...  
WO/2014/146082A1
Methods, apparatus, compositions and kits for inhibiting a disorder in a human patient, including non-cerebral neurovascular disorder or muscular headache pain, or loss of motor or sensory function, sympathetic tone or range or fluidity ...  
WO/2014/138791A1
The present invention relates to transgenic animal models. Specifically, the present invention relates to transgenic animal models for applications associated with TSPO-related normal physiology, diseases and disorders. The present inven...  
WO/2014/139882A1
The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 ...  
WO/2014/145118A1
Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative di...  
WO/2014/144100A3
Compounds of Formulae (I') and (I) are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders tha...  
WO/2014/140186A1
The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.  
WO/2014/142519A1
The present invention provides a pharmaceutical composition for preventing and/or treating a epilepsy or epilepsy-related syndrome, for example an intractable epilepsy or its related syndrome such as drug-resistant epilepsy, comprising t...  
WO/2014/142548A1
The present invention relates to a composition for preventing or treating a nerve gas-induced disease comprising a phenyl carbamate compound and a method for preventing or treating a nerve gas-induced disease therewith. The present inven...  
WO/2014/139150A1
The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present...  
WO/2014/143666A1
Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I).  
WO/2014/143799A3
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.  
WO/2014/142520A1
The present invention provides a pharmaceutical composition for preventing and/or treating a epilepsy or epilepsy-related syndrome, for example an intractable epilepsy or its related syndrome such as drug-resistant epilepsy, comprising t...  
WO/2014/139227A1
A lump sugar contains monosialotetera-hexosyl ganglioside of 0.01-3% by weight, brain protein of 1-98% by weight, and chicory polysaccharide of 1-98% by weight.  
WO/2014/142477A1
The present invention provides a pharmaceutical composition for preventing and/or treating a pediatric epilepsy or epilepsy-related syndrome comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbam...  
WO/2014/138814A1
The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can al...  
WO/2014/141219A1
The present invention relates to umbilical cord blood derived mesenchymal stem cells (UCBMSCs) for use in treating a neural disorder in a subject such as a placental mammal, wherein said cells are to be administered by (i) intravenous ad...  
WO/2014/141261A1
The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, o...  
WO/2014/140313A1
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, f...  
WO/2014/138772A1
The present invention provides a crystalline Form B of compound 1, and pharmaceutically compositions thereof. The present invention also provides methods of treating a disease (e.g., a disease of the central nervous system) using the pha...  
WO/2014/140235A1
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 kinase, for use in the diagnosis, prevention and/or treatment of LRRK2 -k...  
WO/2014/144330A1
The invention relates to methods for treating stress sensitive condition, particularly deppression. For instance a subject having or at risk of having depression may be treated with a growth hormone (GH) or an agonist thereof in an effec...  
WO/2014/141265A1
A composition is provided comprising extracts of at least grape seeds (GSE) and green tea. The extracts are preferably polyphenolic and preferably comprises probiotic bacteria. The use of extracts from green tea and grape seeds for the m...  
WO/2014/144765A1
The instant invention relates to seaweed extract compositions, processes for isolation, isolated active agents, and methods of treating disease, disorders and conditions in a subject, including, reactive oxygen species (ROS)- mediated di...  
WO/2014/144632A3
Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies an...  
WO/2014/144027A1
Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores ar...  
WO/2014/144409A1
The present disclosure provides methods of modulating a feature of a behavioral state. The methods involve inhibiting or activating the activity of a bed nucleus of stria terminalis (BNST) neuron, a BNST subnucleus, or a neuronal output ...  
WO/2014/142290A1
Provided is a compound as represented by formula [I] [in which n indicates 1 or 2], formula [II] or [IIh], or formula [III], or a pharmaceutically acceptable salt thereof. Also provided are medicinal uses for the compound or the salt the...  
WO/2014/144426A1
Methods for helping to monitor subject adherence with a prescribed antipsychotic drug treatment regimen are disclosed. In various embodiments, the present invention provides methods for helping monitor patient adherence to aripiprazole t...  
WO/2014/143380A1
An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneou...  
WO/2014/142276A1
The objective of the present invention is to provide a compound having a superior neurotrophic factor-like effect. The present invention provides a medicine containing the compound as the active ingredient. The present invention pertains...  
WO/2014/143985A1
Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB recept...  
WO/2014/141065A1
The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical...  
WO/2014/146044A1
Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood l...  
WO/2014/142322A1
[Problem] To provide: a compound having a novel structure and having PDE10A inhibitory activity, an isotope thereof, or a pharmaceutically acceptable salt thereof; and a medicinal composition containing same as the active ingredient. [So...  

Matches 201 - 250 out of 103,211